PSIL Fact Sheet: AdvisorShares Psychedelics ETF
Share
$16.68
close, Nov 20, 2026
Over the year to Nov 19, 2026, PSIL returned +8.2% in total and charged 1.00% a year.
- 1-year total return
- +6.0%
- to Nov 20, 2026
- Expense ratio
- 1.00%
- a year
- Net assets
- $38m
- on Nov 19, 2026
- Net flow, last 4 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
PSIL $10,816 +8.2% · VOO $11,147 +11.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−20.6%
3 months−35.5%
Year to date−2.9%
1 year+6.0%
3 years+40.2%
5 years−76.5%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
DEFINIUM THERAPEUTICS INC12.85%
COMPASS PATHWAYS PLC11.45%
ATAIBECKLEY INC10.47%
RELMADA THERAPEUTICS INC6.84%
NRX PHARMACEUTICALS INC6.07%
NEUROCRINE BIOSCIENCES INC4.38%
CYBIN INC4.36%
GH RESEARCH PLC4.31%
ALKERMES PLC4.30%
ALTO NEUROSCIENCE INC4.20%
PSIL top ten by weight, 69.2% of the fund, of its 27 equity positions, from the holdings filed for Jun 30, 2026.
Facts
Holds 27 stocks in therapeutics and medical devices, 8% of its weight in S&P 500 companies · First traded Sep 16, 2021 · Benchmark Its own holdings, as of Jun 30, 2026